IP Library › Granted Patent US 12,624,121
Granted Patent B2
US 12,624,121 · App. 18/339,145 · Granted May 12, 2026

Assays for TIMP2 having improved performance in biological samples

Inventors: Ravi A. Vijayendran (San Diego, CA); Srivatsa Venkatasubbarao (Sammamish, WA)
Assignee: bioMerieux, Inc.
C07K16/3015G01N33/5758C07K2317/20C07K2317/34C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,624,121
App. No.
18/339,145
Granted
May 12, 2026
Kind
B2
Abstract

The present invention relates to antibodies or antigen binding fragments thereof that binds to human “TIMP2. Further provided are methods for treating subjects, including human subjects, in need of treatment with the isolated TIMP2 antibodies or antigen-binding fragments thereof disclosed herein. Further provided are pharmaceutical or sterile compositions of anti-TIMP2 antibodies and antigen-binding fragments of the invention, the antibody or antigen-binding fragment thereof is admixed with a pharmaceutically acceptable carrier or excipient. Further provided are kits comprising one or more components that include an anti-TIMP2 antibody or antigen-binding fragment thereof of the invention or a pharmaceutical composition thereof.

Claims (27)

1 . A monoclonal antibody that binds to human tissue inhibitor of metalloproteinases 2 (TIMP2) protein, wherein the antibody comprises:

(a) a light chain variable region complementarity determining region 1 (CDR1) comprising the amino acid sequence DHINNW (SEQ ID NO: 24), a light chain variable region CDR2 comprising the amino acid sequence SGA, and a light chain variable region CDR3 comprising the amino acid sequence QQYWSTPFT (SEQ ID NO: 26); and

(b) a heavy chain variable region CDR1 comprising the amino acid sequence GYSFTSYW (SEQ ID NO: 27), a heavy chain variable region CDR2 comprising the amino acid sequence IDPSDSET (SEQ ID NO: 28), and a heavy chain variable region CDR3 comprising the amino acid sequence ARRDYGSRYDAMDY (SEQ ID NO: 29).

2 . The monoclonal antibody of claim 1 , wherein the light chain variable region comprises an amino acid sequence at least 90% identical to that set forth as SEQ ID NO: 30 and the heavy chain variable region comprises an amino acid sequence at least 90% identical to that set forth as SEQ ID NO: 31.

3 . The monoclonal antibody of claim 2 , wherein the light chain variable region comprises an amino acid sequence set forth as SEQ ID NO: 30 and the heavy chain variable region comprises an amino acid sequence set forth as SEQ ID NO: 31.

4 . The monoclonal antibody of claim 1 , wherein the light chain comprises an amino acid sequence at least 90% identical to that set forth as SEQ ID NO: 39 and the heavy chain comprises an amino acid sequence at least 90% identical to that set forth as SEQ ID NO: 33.

5 . The monoclonal antibody of claim 4 , wherein the light chain comprises an amino acid sequence set forth as SEQ ID NO: 39 and the heavy chain comprises an amino acid sequence set forth as SEQ ID NO: 33.

6 . The monoclonal antibody of claim 1 , wherein the antibody is a rabbit antibody.

7 . The monoclonal antibody of claim 1 , wherein the antibody is conjugated to a signal development element.

8 . The monoclonal antibody of claim 1 , wherein the antibody is immobilized on a solid support.

9 . The monoclonal antibody of claim 1 , wherein one of the first and the second monoclonal antibodies is immobilized on a solid support.

10 . A rabbit monoclonal antibody comprising a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 30 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 31.

11 . A method for determining the presence or amount of human tissue inhibitor of metalloproteinases 2 (TIMP2) protein in a biological sample, the method comprising:

performing an immunoassay on the biological sample with first and second monoclonal antibodies which together form sandwich complexes with human TIMP2 protein, wherein the immunoassay provides a detectable signal that is related to the presence or amount of human TIMP2 protein in the biological sample bound in the sandwich complexes; and

relating the detectable signal to the presence or amount of human TIMP2 protein in the biological sample,

wherein the first monoclonal antibody comprises:

(a) a light chain variable region complementarity determining region 1 (CDR1) comprising the amino acid sequence DHINNW (SEQ ID NO: 24), a light chain variable region CDR2 comprising the amino acid sequence SGA (SEQ ID NO: 25), and a light chain variable region CDR3 comprising the amino acid sequence QQYWSTPFT (SEQ ID NO: 26); and

(b) a heavy chain variable region CDR1 comprising the amino acid sequence GYSFTSYW (SEQ ID NO: 27), a heavy chain variable region CDR2 comprising the amino acid sequence IDPSDSET (SEQ ID NO: 28), and a heavy chain variable region CDR3 comprising the amino acid sequence ARRDYGSRYDAMDY (SEQ ID NO: 29).

12 . The method of claim 11 , wherein the first monoclonal antibody comprises a light chain variable region comprising an amino acid sequence at least 90% identical to that set forth as SEQ ID NO: 30 and a heavy chain variable region comprising an amino acid sequence at least 90% identical to that set forth as SEQ ID NO: 31.

13 . The method of claim 12 , wherein the light chain variable region comprises an amino acid sequence set forth as SEQ ID NO: 30 and the heavy chain variable region comprises an amino acid sequence set forth as SEQ ID NO: 31.

14 . The method of claim 11 , wherein the first monoclonal antibody comprises a light chain comprising an amino acid sequence at least 90% identical to that set forth as SEQ ID NO: 39 and a heavy chain comprising an amino acid sequence at least 90% identical to that set forth as SEQ ID NO: 33.

15 . The method of claim 14 , wherein the light chain comprises an amino acid sequence set forth as SEQ ID NO: 39 and the heavy chain comprises an amino acid sequence set forth as SEQ ID NO: 33.

16 . The method of claim 11 , wherein the first monoclonal antibody is a rabbit antibody.

17 . The method of claim 11 , wherein one of the first and the second monoclonal antibodies is conjugated to a signal development element.

18 . The method of claim 11 , wherein the minimum detectable concentration is 10 ng/ml or less.

19 . The method of claim 11 , wherein the immunoassay is performed in a lateral flow format.

20 . The method of claim 11 , wherein the immunoassay is performed by applying the biological sample to a disposable test device, and the detectable signal is obtained by inserting the disposable test device into an analytical instrument, wherein the sandwich complexes comprising the first and second antibodies are immobilized for detection in a predetermined zone of the disposable test device, and wherein the analytical instrument detects the immobilized sandwich complexes to provide the detectable signal.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2025
From: ASTUTE MEDICAL, INC.
To: BIOMERIEUX, INC.
Reel/Frame 069778/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2023
From: VIJAYENDRAN, RAVI A.; VENKATASUBBARAO, SRIVATSA
To: ASTUTE MEDICAL, INC.
Reel/Frame 064024/0899 →
Continuity (3)
Division 16603071
Provisional Application 62482089 · Apr 5, 2017
Related Publication 20240002529A1 · Jan 4, 2024
References Cited (164)
US 5698671A · Stetler-Stevenson et al. · 1997 [cited by applicant]
US 6391265B1 · Buechler et al. · 2002 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 7097983B2 · Markovsky et al. · 2006 [cited by applicant]
US 7125493B2 · Wang et al. · 2006 [cited by applicant]
US 7214542B2 · Hutchinson · 2007 [cited by applicant]
US 8778615B2 · Anderberg et al. · 2014 [cited by applicant]
US 9360488B2 · Anderberg et al. · 2016 [cited by applicant]
US 9459261B2 · Anderberg et al. · 2016 [cited by applicant]
US 9784750B2 · Anderberg et al. · 2017 [cited by applicant]
US 9822172B2 · Vijayendran et al. · 2017 [cited by applicant]
US 9879091B2 · Vijayendran et al. · 2018 [cited by applicant]
US 10300108B2 · Mcpherson et al. · 2019 [cited by applicant]
US 10457744B2 · Vijayendran et al. · 2019 [cited by applicant]
US 10457774B2 · Small et al. · 2019 [cited by applicant]
US 20020034765A1 · Daugherty et al. · 2002 [cited by applicant]
US 20060094061A1 · Brys et al. · 2006 [cited by applicant]
US 20060099684A1 · Moses et al. · 2006 [cited by applicant]
US 20070031286A1 · Miike et al. · 2007 [cited by applicant]
US 20100009462A1 · Christ et al. · 2010 [cited by applicant]
US 20100010201A1 · Silbiger et al. · 2010 [cited by applicant]
US 20120283128A1 · Anderberg et al. · 2012 [cited by applicant]
US 20130052655A1 · Kobayashi et al. · 2013 [cited by applicant]
US 20130157881A1 · Anderberg et al. · 2013 [cited by applicant]
US 20140377777A1 · Anderberg et al. · 2014 [cited by applicant]
US 20150086558A1 · Chang et al. · 2015 [cited by applicant]
US 20160146832A1 · Chawla et al. · 2016 [cited by applicant]
US 20160257762A1 · Kwon et al. · 2016 [cited by applicant]
US 20160281083A1 · Niitsu et al. · 2016 [cited by applicant]
US 20160297893A1 · Vijayendran et al. · 2016 [cited by applicant]
US 20170199182A1 · Lee · 2017 [cited by applicant]
US 20170248613A1 · Anderberg et al. · 2017 [cited by applicant]
US 20180074054A1 · Mcpherson et al. · 2018 [cited by applicant]
US 20190263926A1 · Mcpherson et al. · 2019 [cited by applicant]
US 20190302131A1 · Mcpherson et al. · 2019 [cited by applicant]
US 20200071416A1 · Vijayendran et al. · 2020 [cited by applicant]
US 20200103415A1 · Anderberg et al. · 2020 [cited by applicant]
JP H05244985 · 1993 [cited by applicant]
JP 2002507725A · 2002 [cited by applicant]
JP 2008516593A · 2008 [cited by applicant]
WO WO199011287 · 1990 [cited by applicant]
WO WO199211018 · 1992 [cited by applicant]
WO WO199633735 · 1996 [cited by applicant]
WO WO199634096 · 1996 [cited by applicant]
WO WO199824893 · 1998 [cited by applicant]
WO WO199947930 · 1999 [cited by applicant]
WO WO2006010529 · 2006 [cited by applicant]
WO WO2007048100 · 2007 [cited by applicant]
WO WO2007048102 · 2007 [cited by applicant]
WO WO2010048346 · 2010 [cited by applicant]
WO WO2011047346 · 2011 [cited by applicant]
WO WO2011075744 · 2011 [cited by applicant]
WO WO2011097539 · 2011 [cited by applicant]
WO WO2011162821 · 2011 [cited by applicant]
WO WO2013043310 · 2013 [cited by applicant]
WO WO2013086359 · 2013 [cited by applicant]
WO WO2014031476 · 2014 [cited by applicant]
WO WO2014113558 · 2014 [cited by applicant]
WO WO2014197729 · 2014 [cited by applicant]
WO WO2015021308 · 2015 [cited by applicant]
WO WO2015069880 · 2015 [cited by applicant]
WO WO2015084939 · 2015 [cited by applicant]
WO WO2016164854 · 2016 [cited by applicant]
WO WO2017214203 · 2017 [cited by applicant]
WO WO2018081578 · 2018 [cited by applicant]
WO WO2018145117 · 2018 [cited by applicant]
WO WO2018187453 · 2018 [cited by applicant]
WO WO2018208684 · 2018 [cited by applicant]
Aitken, “Antibody Phage Display,” Molecular Biomethods Handbook, 2nd Edition, Humana Press, 2008, pp. 563-564. [cited by applicant]
Anonymous, “Question (52796): Anti-TIMP2 antibody (ab53730),” Abram, Jun. 29, 2012, Retrieved from the Internet: URL:http://www.abcam.comITIMP2-antibody-ab53730/questions/52796 [retrieved on Apr. 5, 2017]. [cited by applicant]
Baca et al., “Antibody Humanization Using Monovalent Phage Display,” J Biol Chem, Apr. 18, 1997, 272(16):10678-10684. [cited by applicant]
Baldridge et al., “Monophosphoryl Lipid A (MPL) Formulations for the Next Generation of Vaccines,” Methods, 1999, 19:103-107. [cited by applicant]
Bieg et al., “GAD65 and Insulin B Chain Peptide (9-23) are not Primary Autoantigens in the Type 1 Diabetes Syndrome pf the BB Rat,” Autoimmunity, 1999, 31:15-24. [cited by applicant]
Bitter et al., “Expression and Secretion Vectors for Yeast,” Methods Enzymol, 1987, 153:516-544. [cited by applicant]
Bodden et al., “Functional Domains of Human TIMP-1 (Tissue Inhibitor of Metalloproteinases),” J Biol Chem, Jul. 22, 1994, 269(29):18943-18952. [cited by applicant]
Bradbury et al., “Beyond natural antibodies: the power of in vitro display technologies,” Nat Biotechnol, Mar. 2011, 29(3):245-254. [cited by applicant]
Brown et al., “Antigen retrieval incryostat tissue sections and cultured cells by treatment with sodium dodecyl sulfate (SDS),” Histochem Cell Biol, 1996, 105:261-267. [cited by applicant]
Brüggemann et al., “Production of human antibody repertoires in transgenic mice,” Curr Opin Biotechnol, 1997, 8:455-458. [cited by applicant]
Campbell, Monoclonal Antibody Technology, Elsevier Sci Publication, 1984, 15 pp. [cited by applicant]
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc Natl Acad Sci USA, May 1992, 89:4285-4289. [cited by applicant]
Caterina et al., “Inactivating Mutation of the Mouse Tissue Inhibitor of Metalloproteinases-2(Timp-2) Gene Alters ProMMP-2 Activation,” J Biol Chem, Aug. 25, 2000, 275(34):26416-26422. [cited by applicant]
Cockett et al., “High Level Expression of Tissue Inhibitor of Metalloproteinases in Chinese Hamster Ovary Cells Using Glutamine Synthetase Gene Amplification,” Biotechnology, Jul. 1990, 8:662-667. [cited by applicant]
Colbere-Garapin et al., “A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells,” J Mol Biol, 1981, 150:1-14. [cited by applicant]
Crouse et al., “Expression and Amplification of Engineered Mouse Dihydrofolate Reductase Minigenes,” Mol Cell Biol, Feb. 1983, 3:257-266. [cited by applicant]
Cwirla et al., “Peptides on phage: A vast library of peptides for identifying ligands,” Proc Natl Acad Sci USA, Aug. 1990, 87:6378-6382. [cited by applicant]
De Pascalis et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” … [cited by applicant]
Devlin et al., “Random Peptide Libraries: A Source of Specific Protein Binding Molecules,” Science, 1990, 249:404-406. [cited by applicant]
Dondelinger et al., “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition,” Front. Immunol., Oct. 2018, 9:2278, doi: 10.3389/fimmu.2018.02278, 15 pp. [cited by applicant]
Edwards et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS,” J. Mol. Biol., 2003, 334: 103-118. [cited by applicant]
Eton et al., “Active Immunotherapy with Ultraviolet B-Irradiated Autologous Whole Melanoma Cells plus Detox in Patients with Metastatic Melanoma,” Clin Cancer Res, Mar. 1998, 4:619-627. [cited by applicant]
Fischer et al., “A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis,” Intensive Care Med, 2003, 29:1043-1051. [cited by applicant]
Foecking et al., “Powerful and versatile enhancer-promoter unit for mammalian expression vectors,” Gene, 1986, 45:101-105. [cited by applicant]
Fujimoto et al., “Determination of tissue inhibitor of metalloproteinases-2 (TIMP-2) in experimental animals using monoclonal antibodies against TIMP-2-specific oligopeptides,” Journal of Immunological Methods, 1995, 18… [cited by applicant]
Fujimoto et al., “A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies,” Clinica Chimica Acta, 1993, 220:31-45. [cited by applicant]
Gorman et al., “Reshaping a therapeutic CD4 antibody,” Proc Natl Acad Sci USA, May 1991, 88:4181-4185. [cited by applicant]
Greene et al., “Molecular Cloning and Characterization of Human Tissue Inhibitor of Metalloproteinase 4,” J Biol Them, Nov. 29, 1996, 271(48):30375-30380. [cited by applicant]
Griffiths et al., “Strategies for selection of antibodies by phage display,” Curr Opin Biotechnol. 1998, 9:102-108. [cited by applicant]
Gupta et al., “Adjuvants for human vaccines—current status, problems and future prospects,” Vaccine, 1995, 13(14):1263-1276. [cited by applicant]
Harlow et al., “Antibodies a Laboratory Manual,” Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1988, pp. 141-155. [cited by applicant]
He et al., “Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-Selectin,” J Immunol, 1998, 160:1029-1035. [cited by applicant]
Inouye et al.,“Up-promoter mutations in the lpp gene of [cited by applicant]
Johnson et al., “3-0-Desacyl Monophosphoryl Lipid A Derivatives: Synthesis and Immunostimulant Activities,” J Med Chem, 1999, 42:4640-4649. [cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, May 29-Jun. 4, 1986, 321:522-525. [cited by applicant]
Kohler, “Immunoglobulin chain loss in hybridoma lines,” Proc Natl Acad Sci USA, Apr. 1980, 77(4):2197-2199. [cited by applicant]
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, Aug. 7, 1975, 256:495-497. [cited by applicant]
Krauss et al., “Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment,” Protein Eng, 2003, 16(10):753-759. [cited by applicant]
Larsen et al., “Quantification of Tissue Inhibitor of Metalloproteinases 2 in Plasma from Healthy Donors and Cancer Patients,” Scand J Immunol, 2005, 61:449-460. [cited by applicant]
Lodmell et al., “DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL),” Vaccine, 2000, 18:1059-1066. [cited by applicant]
Logan et al., “Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection,” Proc Natl Acad Sci USA, Jun. 1984, 81:3655-3659. [cited by applicant]
Lonberg et al., “Human Antibodies From Transgenic Mice,” Intern Rev Immunol, 1995, 13:65-93. [cited by applicant]
Lowy et al., “Isolation of Transforming DNA: Cloning the Hamster aprt Gene,” Cell, Dec. 1980, 22:817-823. [cited by applicant]
Meyer et al., “New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies,” British Journal of Haematology, 2018, 180:808-820. [cited by applicant]
Morgan et al., “Human Gene Therapy,” Annu Rev Biochem, 1993, 62:191-217. [cited by applicant]
Morlacchi et al., “Self-antigen presentation by mouse B cells results in regulatory T-cell induction rather than anergy or clonal deletion,” Blood, Jul. 28, 2011 , 118(4):984-991. [cited by applicant]
Mulligan, “The Basic Science of Gene Therapy,” Science, May 14, 1993, 260:926-932. [cited by applicant]
Mulligan et al., “Selection for animal cells that express the [cited by applicant]
Nelson et al., “A computer program for calculating antibody affinity constants,” Comput Methods Programs Biomed, 1988, 27:65-68. [cited by applicant]
Nie et al., “Rapid detection of TIMP-2 in serum of patients with hepatitis by monoclonal antibody double antibody sandwich Elisa,” Chinese Journal of Gastroenterology and Hepatology, Dec. 2005, 14(6):577-580 (machine tr… [cited by applicant]
O'Connor et al., “Humanization of an antibody against human protein C and calcium-dependence involving framework residues,” Protein Eng, 1998, 11(4):321-328. [cited by applicant]
Ofran et al., “Automated Identification of Complementarity Determining Regions (CDRs) Reveals Peculiar Characteristics of CDRs and B Cell Epitopes,” J Immunol, 2008, 181(9):6230-6235. [cited by applicant]
O'Hare et al., “Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase,” Proc Natl Acad Sci USA, Mar. 1981, 78(3):1527-1531. [cited by applicant]
Presta et al., “Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders,” Cancer Res, Oct. 15, 1997, 57:4593-4599. [cited by applicant]
Proudfoot, “Transcriptional interference and termination between duplicated alpha-globin gene constructs suggests a novel mechanism for gene regulation,” Nature, 1986, 322:562-565. [cited by applicant]
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc Natl Acad Sci USA, Dec. 1989, 86:10029-10033. [cited by applicant]
R&D Systems Inc., “Quantikine Elisa Human TIMP-2 Immunoassay,” Cat # DTM200, Oct. 1, 2016, KP055361590, retrieved from the Internet: URL:https://resources.mndsystems.com/pdfs/datasheets/dtm200.pdf retrieved on Apr. 4, 2… [cited by applicant]
Rader et al., “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,” Proc Natl Acad Sci USA, Jul. 1998, 95:8910-8915. [cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy,” Nature, Mar. 1988, 332:323-327. [cited by applicant]
Roguska et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing,” Proc Natl Acad Sci USA, Feb. 1994, 91:969-973. [cited by applicant]
Roque et al., “Antibodies and Genetically Engineered Related Molecules: Production and Purification,” Biotechnol Prog, 2004, 20:639-654. [cited by applicant]
Rosok et al., “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,” J Biol Chem, Sep. 13, 1996, 271(37)22611-22618. [cited by applicant]
Rossi et al., “A Comparative Study Between a Novel Category of Immunoreagents and the Corresponding Mouse Monoclonal Antibodies,” Am J Clin Pathol, 2005, 124:295-302. [cited by applicant]
Rothe et al., “The Human Combinatorial Antibody Library HuCAL Gold Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Affinity Ant… [cited by applicant]
Ruther et al., “Easy identification of cDNA clones,” EMBO J, 1983, 2(10):1791-1794. [cited by applicant]
Santerre et al., “Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells,” Gene, 1984, 30:147-156. [cited by applicant]
Scott et al., “Searching for Peptide Ligands with an Epitope Library,” Science, 1990, 249:386-390. [cited by applicant]
Szybalska et al., “Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait,” Proc Natl Acad Sci USA, 1962, 48:2026-2034. [cited by applicant]
Tachibana et al., “Altered reactivity of immunoglobulin produced by human-human hybridoma cells transfected by pSV2-neo gene,” Cytotechnology, 1991, 6:219-226. [cited by applicant]
Talvensaari-Mattila et al., “Levels of Circulating TIMP-2 and MMP2-TIMP2 Complex Are Decreased in Squamous Cervical Carcinoma,” Obstetrics and Gynecology International, Feb. 21, 2010, vol. 2010:179351, 3 pp. [cited by applicant]
Tan et al., “Superhumanized Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28,” J Immunol, 2002, 169:1119-1125. [cited by applicant]
Tiller et al., “Advances in Antibody Design,” Annu Rev Biomed Eng, 2015;17:191-216 doi: 10.1146/annurev-bioeng-071114-040733. [cited by applicant]
Tolstoshev, “Gene Therapy, Concepts, Current Trials and Future Directions,” Annu Rev Pharmacol Toxicol, 1993, 33:573-596. [cited by applicant]
Tsurushita et al., “Humanization of Monoclonal Antibodies,” Molecular Biology of B Cells, 2004:533-545. [cited by applicant]
Vajdos et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J. Mol. Biol., 2002, 320:415-428. [cited by applicant]
Van Erp et al., “Application of a Sol Particle Immunoassay to the Determination of Affinity Constants of Monoclonal Antibodies,” J Immunoassay, 1991, 12(3):425-443. [cited by applicant]
Van Heeke et al., “Expression of Human Asparagine Synthetase in [cited by applicant]
Verhoeyen et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” Science, 1988, 239:1534-1536. [cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Wigler et al., “Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells,” Cell, May 1977, 11:223-232. [cited by applicant]
Wigler et al., “Transformation of mammalian cells with an amplifiable dominant-acting gene,” Proc Natl Acad Sci USA, Jun. 1980, 77(6):3567-3570. [cited by applicant]
Wilson et al., “Simplified conjugation chemistry for coupling peptides to F(ab') fragments: autologous red cell agglutination assay for HIV-1 antibodies,” J Immunol Methods, 1994, 175:267-273. [cited by applicant]
Wu et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J Mol Biol, 1999, 294:151-162. [cited by applicant]
Yarmush et al., “Coupling of antibody-binding fragments to solid-phase supports: site-directed binding of F(ab')2 fragments,” J Biochem Biophys Methods, 1992, 25:285-297. [cited by applicant]
Zucker et al., “Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) Binds to the Catalytic Domain of the Cell Surface Receptor, Membrane Type 1-Matrix Metalloproteinase 1 (MT1-MMP),” J of Biolog Chem, Jan. 9, 1998, 273(2):… [cited by applicant]
Official Action issued Feb. 8, 2023 in Chinese Application No. 201880034638.3. [cited by applicant]
Copy of International Search Report and Written Opinion issued on Sep. 10, 2018 in PCT/US2018/026058. [cited by applicant]
Official Action issued Feb. 8, 2022 in Japanese Application No. 2019-554789. [cited by applicant]
Anne et al., “Levels of Circulating TIMP-2 and MMP2-TIMP2 Complex Are Decreased in Squamous Cervical Carcinoma”, Obstet Gynecol Int. 2010;2010:179351. doi: 10.1155/2010/179351. Epub Jun. 29, 2010. [cited by applicant]
Brown et al. (“Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?”, J Immunol. May 1996;156(9):3285-91) (Year: 1996). [cited by applicant]
Extended European Search Report and Written Opinion issued in EP 14834090 dated Apr. 18, 2017. [cited by applicant]
International Preliminary Report on Patentability issued in PCT/US2014/050195 dated Feb. 18, 2016. [cited by applicant]
European Search Report and Search Opinion received for European Application No. 18781904.0, mailed on Nov. 5, 2020, 8 pages. [cited by applicant]
Extended European Search Report and Search Opinion received for European Application No. 19183111.4, mailed on Nov. 11, 2019, 13 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US18/26058, mailed on Oct. 17, 2019, 7 pages. [cited by applicant]
International Search Report and Written Opinion issued Dec. 16, 2014 in PCT/US2014/050195 (9 pages). [cited by applicant]